

University of Kentucky UKnowledge

Nursing Presentations

College of Nursing

3-2014

Evidence-Based Smoking Cessation Treatment for Disparate Populations

Chizimuzo T.C. Okoli University of Kentucky, ctokol1@uky.edu

Click here to let us know how access to this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/nursing_present



Part of the Nursing Commons, and the Public Health Commons

Repository Citation

Okoli, Chizimuzo T.C., "Evidence-Based Smoking Cessation Treatment for Disparate Populations" (2014). Nursing Presentations. 4. https://uknowledge.uky.edu/nursing_present/4

This Presentation is brought to you for free and open access by the College of Nursing at UKnowledge. It has been accepted for inclusion in Nursing Presentations by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Evidence-Based Smoking Cessation Treatment for Disparate Populations

Chizimuzo Okoli, PhD, MPH, RN Assistant Professor and Director, Tobacco Treatment and Prevention Division, Tobacco Policy Research Program, University of Kentucky College of Nursing

Overview

- Describe Research Group and Program of Research among disparate Populations
- Discuss smoking among persons with substance use and mental illness
- Present smoking cessation outcomes from evidencebased programs for persons with substance use disorders and mental Illness
- Conclusion with current and future Projects

RESEARCH GROUP AND PROGRAM OF RESEARCH



Clean Indoor Air Partnership



Air Quality Monitoring



Freedom from Radon Exposure and Smoking in the Home (FRESH)

Radon Policy Research Program







Kentucky Center for Smoke-Free Policy







Rural Smoke-Free Communities Projec





Tobacco Treatment and Prevention Program





Program of Research

Secondhand Smoke & Smoking Behaviours

Tobacco Treatment In for people with Mental illness (Participation Station)

Tobacco Treatment
within
Outpatient Services in
Hospitals
(VGH SCC)

Tobacco
Treatment and
Prevention
Division


Smoking cessation program for Homeless persons (HOPE Center)

Developing Tailored tobacco treatment for individuals with mental illness

Smoking cessation program within outpatient Psychiatric Services (BREATHE UK)

SMOKING AMONG PERSONS WITH SUBSTANCE USE AND MENTAL ILLNESS

Background and Significance






 "Nicotine-dependent individuals with a comorbid psychiatric disorder made up 7.1% of the population yet consumed 34.2% of all cigarettes smoked in the United States"




Grant, B.F., Hasin, D.S., Chou, S.P., Stinson, F.S.& Dawson, D.A. (2004). Nicotine dependence and psychiatric disorders in the United States: Results from a national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry,61,1107-1115.



^{*} Difference between those with any mental illness and those with no mental illness is statistically significant at the .05 level.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Surveys on Drug Use and Health (NSDUHs), 2009 to 2010 (revised March 2012), 2011.

Past Month Cigarette Use among Adults Aged 18 or Older, by Any Mental Illness in the Past Year and Gender, by Age Group: 2009 to 2011



Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123

Health effects of smoking among persons with mental illness

Smokers with Mental illness:

- Die 10 years earlier
- Have more depression and depression
- Have more substance use problems
- Have more chest and heart problems
- Are more likely to commit suicide
- Have sexual probles

Nonsmokers with Mental illness:


- Have better health
- Live longer
- Need less medication
- Have less depression
- Save more money

Reasons for smoking among individuals with substance use disorders and mental illness

Genetic



Bio-behavioral





Psychosocial



Smoking and substance use: Genetic



Familial Transmission of Substance Dependence: Alcohol, Marijuana, Cocaine, and Habitual Smoking A Report From the Collaborative Study on the Genetics of Alcoholism

Laura Jean Bierut, MD; Stephen H. Dinwiddie, MD; Henri Beg Victor Hesselbrock, PhD; John I. Nurnberger, Jr, MD, PhD; Be Marc A. Schuckit, MD; Theodore Reich, MD

Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men

William R True, PhD, MPH; Hong Xian, PhD; Jeffrey F. Scherrer, MA; Pamela A. F. Madden, PhD; Kathleen K. Bucholz, PhD; Andrew C. Heath, DPhil; Seth A. Eisen, MD, MSc; Michael J. Lyons, PhD; Jack Goldberg, PhD; Ming Tsuang, MD, PhD, DSc

- Both common and specific addictive factors for alcohol, marijuana, cocaine, and habitual smoking transmitted in families
- This specificity suggested independent causative factors for the development of each substance dependence
- 68% of the association between nicotine and alcohol dependence explained by shared genetic effects.

Bierut LJ, Dinwiddie SH, Begleiter H, et al. Familial Transmission of Substance Dependence: Alcohol, Marijuana, Cocaine, and Habitual Smoking: A Report From the Collaborative Study on the Genetics of Alcoholism. Archives of General Psychiatry 1998; 55:982-988

True WR. Xian H. Scherrer JF, et al. Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men. Archives of General Psychiatry 1999; 56:655-661



Smoking and mental illness: Genetic

(1,566 female twin pairs) average life time daily cigarette consumption was found to be associated with life time prevalence of major depression, suggesting that the relationship between smoking and major depression resulted solely from genes which predispose to both conditions.

(8,169 male twins) shared genetic disorders further predispose to major depression and nicotine dependence.



Smoking and mental illness: Genetic

A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine Dependence in Men

Karestan C. Koenen, PhD; Brian Hitsman, PhD; Michael J. Lyons, PhD; Raymond Niaura, PhD; Jeanne McCaffery, PhD; Jack Goldberg, PhD; Seth A. Eisen, MD; William True, MD; Ming Tsuang, MD

63% of the association between post traumatic stress disorder and nicotine dependence co-morbidity explained by shared genetic effects.

> A Novel Permutation Testing Method Implicates Sixteen Nicotinic Acetylcholine Receptor Genes as Risk Factors for Smoking in Schizophrenia **Families**

Stephen V. Faraone^{a,b} Jessica Su^b Levi Taylor^c Marsha Wilcox^c Paul Van Eerdewegh^{c,d} Ming T. Tsuang^{a,b,c,e}

A group of candidate genes and individual genes found among individuals with schizophrenia significantly linked to smoking behaviors.

Koenen KC, Hitsman B, Lyons MJ, et al. A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine Dependence in Men. Archives of General Psychiatry 2005; 62:1258-1265 Faraone et al. (2004). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in Schizophrenia families

Smoking and substance use: Bio-behavioral



Marijuana use reduces cessation of tobacco smoking in adults

Ford, Vu, Anthony. (2002) Drug and Alcohol Dependence; 67:243-248

Nicotine increases alcohol self-administration in nondependent male smokers.

Barrett, Tichauer, Leyton, et al. (2006). Drug and Alcohol Dependence; 81:197-204

Increases in methadone dose could increase nicotine craving and cigarette consumption for individuals with opioid-dependence

Story & Stark. (1991). Journal of psychoactive drugs, 23:203-215

Cigarette smoking primes the brain to cocaine use

Levine et al. (2011). Science translational medicine, 3, 107, 107-109

Smoking and mental illness: Bio-behavioral



Nicotine reduces sensorimotor gating deficits in smokers with schizophrenia

Postma et al. (2006). Psychopharmacology, 184: 589-599

Brain levels of monoamine oxidase A (MAO-A) (an enzyme associated with depression) were reduced in smokers relative to nonsmokers; suggesting that people with affective disorders may smoke to reduce elevated MAO-A levels in the brain

Fowler, Volkow, Wang, et al. (1996). Proceedings of the National Academy of Sciences of the United States of America, 93:14065-14069

Smokers with a primary diagnosis of anxiety disorder reported greater levels of general anxiety, distress, and depression as compared to nonsmokers.

McCabe, Chudzik, Antony, et al. (2004). Journal of Anxiety Disorders, 18:7-18

Substance use and Smoking: Psychosocial



 Tobacco use may foster the use of other substances; and vice versa

 Drug treatment centers may provide an environment that supports tobacco use or a factor for delayed tobacco use cessation.

 Factors such as neighborhood disadvantage and early exposure to substance use may present an 'exposure opportunity' for subsequent substance use.

Dependence 1996; 43:155-161

Glautier S, Clements K, White JAW, et al. Alcohol and the reward value of cigarette smoking. Behavioural Pharmacology 1996; 7:144-154
King AC, Epstein AM. Alcohol Dose-Dependent Increases in Smoking Urge in Light Smokers. Alcoholism: Clinical & Experimental Research 2005; 29:547-552
Friend KB, Pagano ME. Smoking initiation among nonsmokers during and following treatment for alcohol u se disorders. Journal of Substance Abuse Treatment 2004; 26:219-224
Bobo JK, Husten C. Sociocultural Influences on Smoking and Drinking. Alcohol Research & Health 2000; 24:225-232
Crum RM, Lillie-Blanton M, Anthony JC. Neighborhood environment and opportunity to use cocaine and other drugs in late childhood and early adolescence. Drug and Alcohol

Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am. J. Epidemiol. 2002: 155:918-925

Smoking mental illness: Psychosocial



 History of tobacco use as a token economy-cigarettes used as a 'reward' for appropriate behavior (i.e., smoking privileges)

 Smoking among clients and staff to encourage 'socialization'

Arguments for Not Providing Tobacco Treatment....

"these patients don't want to quit"

 However....80% of participants in a methadone maintenance program and 75% of participants in an alcohol abuse program endorsed a desire to quit

(Richter KP et al., 2001; Ellingstad TP et al, 1999)

 In a review of 9 studies of motivation to quit smoking among individuals with psychiatric disorders at least 50% are contemplating cessation

(Siru, Hulse & Tait, 2009).

"these patients will relapse (to other substances) if they try to quit"

Smoking cessation related to IMPROVED QUALITY OF LIFE

 Meta-analysis (n = 19 studies) of smoking cessation among individuals in addiction treatment and recovery found that smoking cessation efforts can ENHANCE rather than compromise long-term sobriety

Bobo JK, McIlvain HE, Lando HA, et al. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 1998; 93:877-887

"these patients are unable to quit"

 Meta-analysis (n = 19 studies) of smoking cessation among individuals in addiction treatment and recovery found increased cessation at end of 12 weeks treatment

(Prochaska JJ et al, 2004).

Another recent study found end-of-treatment (between 8 to 26 weeks) smoking cessation rates of 40% among individuals with SUD and/or PD who completed an intensive tailored smoking cessation intervention that provided no-cost pharmacotherapy combined with behavioural counseling

(Khara and Okoli, 2011)

Barriers to facilitating tobacco treatment

- Concerns that smoking cessation will increase psychiatric symptoms or relapse among patients.
 - Among individuals with depression, smoking cessation related to increased depression symptomatology, which is one of the symptoms of the nicotine withdrawal syndrome
 - individuals with anxiety disorders and depression report more severe withdrawal symptoms
 - smoking is associated with improvements in prepulse inhibition and sensory gating which may be affected by smoking cessation
- Smoke-free policy and mental health facilities
 - a review of studies examining prohibitions of smoking in psychiatric facilities suggests that prohibitions do not have longterm effects on behavioral unrest or noncompliance, but neither do they appear to effect smoking cessation

Patten C, Martin J. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine 1996; 18:190-200
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry 1992; 149:464-469

Costs associated with smoking cessation treatment

- Even though less expensive than purchasing cigarettes, the cost of pharmacotherapy and counseling presents an important barrier to seeking treatment
- Such cost barriers to accessing treatment and the potential cost-effectiveness of treatment have prompted guidelines about reducing medication costs (reduced cost or free of charge), inclusion of medications as benefits on drug insurance plans, and setting up systems for reimbursement for tobacco cessation treatment for health care providers.

Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research 2004; 6:303-310

Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing 2006; 15:272-278
Fiore M, Jaén C, Baker T, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive Medicine 2008; 35:158-176

Smoking Cessation Outcomes of evidence-based program for individuals with Substance Use Disorders and Mental Illness



- The Tobacco Dependence Clinic (TDC) for individuals with primarily substance use disorders and addictions
- The Butt-Out Group (Butt-Out) for individuals with primarily mental illnesses

Program Overview

- 24-26 weeks
 - o TDC (8 weeks structured, up to 18 weeks of support)
 - Butt Out group (12 weeks structured, up to 12 weeks support)
- Tailored pharmacotherapy for up to 26 weeks at no cost
- Program is run with a team of nurses, counsellors, respiratory therapists, Occupational therapists, and a physician

TREATMENT PHILOSOPHY

Smoking cessation is a 'process' not an event. Hence the program has no specific 'quit date'. Also the program employs the concept of 'titration-to-effect' in which increasing doses of nicotine replacement therapy is provided until the behavior of smoking ceases.

Criteria


Eligibility:

- 19 years or older
- Tobacco dependent
- Have a history of substance use disorder (SUD) and/or psychiatric disorder (PD)
- Financially disadvantaged

Assessment:

- 1 hour evaluation of medical, psychiatric, substance and tobacco use history
- Expired air CO is determined and a treatment plan is developed in consultation with client

Phases of Treatment



Behavioural Counseling (Weeks 1-8)

- Phase 1: engagement in the process weeks 1-2
- Phase 2: planning for change weeks 3-4
- Phase 3: sustaining change weeks 5-8



Combination Pharmacotherapy

Nicotine Replacement Therapy



Patch



Gum



Lozenge



Inhaler

Oral Medications




Zyban




Champix


Gender



Substance Use Disorder History (either past or current use)




TDC
$$(N = 647)$$



Butt Out Group (N = 76)


Psychiatric Disorder History (either past or current, N = 647)



Butt Out Group (N = 76)

Co-occurring Disorders history


(either past or current)



Sample Characteristics


	TDC (N = 647) Mean (SD)	Butt-Out (N =76) Mean (SD)
Age of participant (years)	47.3 (11.4)	47.2 (10.6)
Age at smoking initiation (years)	14.7 (4.9)	18.1 (6.4)
Importance of quitting (scale of 0 'low' to 10 'high')	9.0 (1.3)	9.0 (1.6)
Confidence in quitting (scale of 0 'low' to 10 'high')	7.3 (2.2)	6.9 (2.3)
Number of cigarettes smoked per day	20.9 (10.5)	22.5 (10.5)
Fagerstrom Test for Nicotine Dependence (scale of 0 'low' to 10 'high')	6.1 (2.1)	6.1 (2.0)
CO level at baseline (ppm)	20.5 (12.6)	22.8 (14.0)

Samples for Outcomes Assessment




Smoking cessation: 7-day point-prevalence of abstinence at end of treatment (i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels

Program Completion




TDC (N = 307/407)




Butt Out Group (N = 64/74)

TDC Smoking Cessation Outcomes at end-of-treatment*



^{*} End-of-treatment (i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels

Butt Out group Smoking Cessation* Outcomes



*End-of-treatment (i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels



Conclusions

- With intensive tobacco dependence treatment provided within Mental Health and Addictions services, individuals with a history of substance use disorders and mental illness are able to achieve smoking abstinence.
- Tobacco treatment should include best practices using behavioural counseling combined with pharmacotherapy.
- Treatment durations beyond 12-weeks should be considered to maximize effectiveness of programs

Current and Future Projects



Current projects:

- Smoking Cessation Program among Individuals with Mental Illness (PARTICIPATION STATION- a peer led mental health support program)
- Understanding the behavioural effects of secondhand tobacco smoke exposure among nonsmokers
- Examining sex and gender differences in tobacco dependence outcomes among smokers with co-occurring substance use and psychiatric disorders

• Future Projects:

- Developing a tailored tobacco dependence treatment program for individuals with Chronic Mental Illnesses
- Examining the effect of different tobacco products on nicotine dependence, symptoms severity, and smoking cessation among individuals with mental illnesses.

Questions??

